Literature DB >> 17222756

Double unrelated reduced-intensity umbilical cord blood transplantation in adults.

Karen K Ballen1, Thomas R Spitzer, Beow Y Yeap, Steven McAfee, Bimalangshu R Dey, Eyal Attar, Richard Haspel, Grace Kao, Deborah Liney, Edwin Alyea, Stephanie Lee, Corey Cutler, Vincent Ho, Robert Soiffer, Joseph H Antin.   

Abstract

Umbilical cord blood (UBC) stem cells are a useful stem cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated with high transplantation-related mortality (TRM). In most cases, mortality is due to infection related to slow engraftment and immunoincompetence. In this study, we used a reduced-intensity conditioning regimen of fludarabine, melphalan, and antithymocyte globulin followed by 2 partially matched UBC units. The UBC units were a 4/6 HLA match or better with each other and with the patient and achieved a minimum precryopreservation cell dose of 3.7 x 10(7) nucleated cells/kg. A total of 21 patients (median age, 49 years) were treated. The median time to an absolute neutrophil count > 0.5 x 10(9)/L was 20 days, and the median time to an unsupported platelet count > 20 x 10(9)/L was 41 days. Two patients experienced primary graft failure and underwent a second UBC transplantation. One patient had a late graft failure. Acute graft-versus-host disease (GVHD) grade II-IV occurred in 40% of patients. The 100-day TRM was 14%, and the 1-year disease-free survival was 67%. Mixed chimerism was associated with a higher risk of chronic GVHD. Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222756      PMCID: PMC2947324          DOI: 10.1016/j.bbmt.2006.08.041

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  28 in total

1.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Authors:  Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment.

Authors:  S A Schichman; P Suess; A M Vertino; P S Gray
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

3.  Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Authors:  H E Broxmeyer; G W Douglas; G Hangoc; S Cooper; J Bard; D English; M Arny; L Thomas; E A Boyse
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

5.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

6.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

7.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

8.  Unrelated umbilical cord blood transplantation in adult patients.

Authors:  Gwynn D Long; Mary Laughlin; Bella Madan; Joanne Kurtzberg; Cristina Gasparetto; Ashley Morris; David Rizzieri; Clayton Smith; James Vredenburgh; Edward C Halperin; Gloria Broadwater; Donna Niedzwiecki; Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2003-12       Impact factor: 5.742

Review 9.  Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.

Authors:  Liang-Piu Koh; Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2004-01       Impact factor: 5.742

Review 10.  Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis.

Authors:  Gerard Michel; Vanderson Rocha; Sylvie Chevret; William Arcese; Kah-Wah Chan; Alexandra Filipovich; Tsuneo A Takahashi; Marcus Vowels; Juan Ortega; Pierre Bordigoni; Peter J Shaw; Isaac Yaniv; Alexandra Machado; Pedro Pimentel; Franca Fagioli; Amparo Verdeguer; Jean Pierre Jouet; Blanca Diez; Euripedes Ferreira; Ricardo Pasquini; Joseph Rosenthal; Eric Sievers; Chiara Messina; Anna Paola Iori; Federico Garnier; Irina Ionescu; Franco Locatelli; Eliane Gluckman
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

View more
  105 in total

Review 1.  Plasticity and maintenance of hematopoietic stem cells during development.

Authors:  Suman Kanji; Vincent J Pompili; Hiranmoy Das
Journal:  Recent Pat Biotechnol       Date:  2011-04

2.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

Review 3.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

4.  A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.

Authors:  U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

5.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

6.  Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.

Authors:  Orly R Klein; Allen R Chen; Christopher Gamper; David Loeb; Elias Zambidis; Nicolas Llosa; Jeffrey Huo; Amy E Dezern; Diana Steppan; Nancy Robey; Mary Jo Holuba; Kenneth R Cooke; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-06       Impact factor: 5.742

7.  Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

Authors:  Koen van Besien; Parameswaran Hari; Mei-Jie Zhang; Hong-Tao Liu; Wendy Stock; Lucy Godley; Olatoyosi Odenike; Richard Larson; Michael Bishop; Amittha Wickrema; Usama Gergis; Sebastian Mayer; Tsiporah Shore; Stephanie Tsai; Joanna Rhodes; Melissa M Cushing; Sandra Korman; Andrew Artz
Journal:  Haematologica       Date:  2016-02-11       Impact factor: 9.941

8.  Donor-derived second hematologic malignancies after cord blood transplantation.

Authors:  Karen K Ballen; Corey Cutler; Beow Y Yeap; Steven L McAfee; Bimalangshu R Dey; Eyal C Attar; Yi-Bin Chen; Richard L Haspel; Deborah Liney; John Koreth; Vincent Ho; Edwin P Alyea; Robert J Soiffer; Thomas R Spitzer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-21       Impact factor: 5.742

9.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

10.  Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency.

Authors:  Sung-Yun Pai; Ofer Levy; Haifa H Jabara; Jonathan N Glickman; Liat Stoler-Barak; Jessica Sachs; Samuel Nurko; Jordan S Orange; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2008-10-11       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.